The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have been saved, if only abandoned discoveries had been given another chance.
Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.
Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...
An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...
Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower low-density lipoprotein cholesterol by more than 55% after 24 weeks. Merck’s ...
Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical company recognized for its strong oncology lineup, led by its flagship drug Keytruda, the top-selling medicine in the world. The ...
SpringWorks Therapeutics, a Merck company, announced that the European Commission has granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of symptomatic, ...
Merck KGaA is still scouting for acquisition targets after the German drug-to-semiconductor group completed its $3.9 billion takeover of SpringWorks Therapeutics Inc. on Tuesday. “The SpringWorks ...
SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business sector. Acquisition marks the formation of a rare tumor business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback